Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 6/20 | 0.58 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | BAX | Q07812 | 1/20 | 0.54 |
| ▸ | PNLIP | P16233 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.48 |
| ▸ | ACACB | O00763 | 2/20 | 0.47 |
| ▸ | ACACA | Q13085 | 2/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28485 | 0.93 | KMT2A (0.56) | KMT2AMEN1ESR1ESR2LTA4H | |
| SCHEMBL6282894 | 0.88 | ALDH1A3 (0.56) | KMT2APNLIPPARP10ACACBACACA | |
| SCHEMBL863444 | 0.86 | ESR2 (0.58) | KMT2AMEN1ESR1ESR2PARP10 | |
| SCHEMBL8002323 | 0.83 | KMT2A (0.47) | KMT2AMEN1ESR1ESR2LTA4H | |
| SCHEMBL12019129 | 0.83 | ESR1 (0.67) | KMT2AMEN1ESR1ESR2PARP10 | |
| SCHEMBL14817450 | 0.81 | ACACB (0.59) | KMT2APNLIPPARP10ACACBACACA | |
| SCHEMBL19847794 | 0.81 | NR1H2 (0.56) | KMT2AMEN1ESR1ESR2NR1H2 | |
| SCHEMBL5197463 | 0.81 | ESR1 (0.56) | KMT2AMEN1ESR1ESR2LTA4H | |
| Hydrogen Peroxide SCHEMBL28902806 | 0.80 | KMT2A (0.70) | KMT2AMEN1PARP10ALDH1A3POLB | |
| SCHEMBL3175106 | 0.80 | ESR2 (1.00) | KMT2AMEN1ESR1ESR2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190181409-A1 | HIGH TEMPERATURE MELT INTEGRITY BATTERY SEPARATORS VIA SPINNING | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2019-06-13 | — | — | US | disclosed |
| US-10243187-B2 | Process of making battery separators via spinning | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2019-03-26 | — | — | US | disclosed |
| US-10030140-B2 | Fiber reinforced polyaryletherketone resin compositions | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2018-07-24 | — | — | US | disclosed |
| US-9577235-B2 | High temperature melt integrity battery separators via spinning | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2017-02-21 | — | — | US | disclosed |
| EP-1996567-B1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8207350-B2 | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBOTT LABORATORIES (US) | 2012-06-26 | — | — | US | disclosed |
| US-7928243-B2 | e.g. N-{(2Z)-3-[4-(4-isopropoxyphenoxy)phenyl]-1-methylprop-2-enyl}acetamide; antidiabetic agent; type II diabetes, atherosclerosis and cardiovascular diseases | ABBOTT LABORATORIES (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2010127208-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-04 | — | — | WO | disclosed |
| US-20090048298-A1 | Novel acetyl-CoA Carboxylase (ACC) Inhibitors and their use in Diabetes, Obesity and Metabolic Syndrome | ABBOTT LABORATORIES (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1996567-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080161368-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008079610-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20070219258-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES | 2007-09-20 | — | — | US | disclosed |
| WO-2007095601-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
| EP-0648729-B1 | Dihalopropene compound, insecticide/acaricide containing said dihalopropene compound as active ingredient and intermediate compound for use in production of said dihalopropene compound | SUMITOMO CHEMICAL CO (JP) | 1998-07-15 | — | — | EP | disclosed |
| US-5698702-A | INTERMEDIATES FOR INSECTICIDES, ACARICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-12-16 | — | — | US | disclosed |
| US-5530015-A | Dihaloprene compound, insecticide/acaricide containing said dihalopropene compound as active ingredient, and intermediate compound for use in production of said dihalopropene compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-06-25 | — | — | US | disclosed |
| EP-0648729-A1 | Dihalopropene compound, insecticide/acaricide containing said dihalopropene compound as active ingredient and intermediate compound for use in production of said dihalopropene compound | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161368-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | KMT2A 3087/4885MEN1 4094/4885ESR1 4134/4885 |
| US-20070219258-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | KMT2A 2737/4885MEN1 3880/4885ESR1 3805/4885 |
| US-20090048298-A1 | Novel acetyl-CoA Carboxylase (ACC) Inhibitors and their use in Diabetes, Obesity and Metabolic Syndrome | ACACA, ACACB, ACAT1 | KMT2A 2737/4885MEN1 3880/4885ESR1 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.